Acetylon Pharmaceuticals is a provider in the development of small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases
Acetylon Pharmaceuticals is a provider in the development of small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company's epigenetic drug discovery platform has yielded a portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds.